MTAC Trademark

Trademark Overview

On Tuesday, November 23, 2021, a trademark application was filed for MTAC with the United States Patent and Trademark Office. The USPTO has given the MTAC trademark a serial number of 97978308. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Thursday, June 20, 2024. This trademark is owned by Avilar Therapeutics, Inc.. The MTAC trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development
mtac

General Information

Serial Number97978308
Word MarkMTAC
Filing DateTuesday, November 23, 2021
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateThursday, June 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, November 29, 2021
Primary Code042
First Use Anywhere DateSaturday, May 4, 2024
First Use In Commerce DateSaturday, May 4, 2024

Trademark Owner History

Party NameAvilar Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameAvilar Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Friday, November 26, 2021NEW APPLICATION ENTERED
Monday, November 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 3, 2022ASSIGNED TO EXAMINER
Tuesday, September 6, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 4, 2023SOU EXTENSION 1 GRANTED
Monday, December 4, 2023SOU EXTENSION 1 FILED
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 6, 2024USE AMENDMENT FILED
Monday, May 6, 2024TEAS STATEMENT OF USE RECEIVED
Monday, May 6, 2024SOU TEAS EXTENSION RECEIVED
Monday, May 6, 2024TEAS REQUEST TO DIVIDE RECEIVED
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 20, 2024DIVISIONAL PROCESSING COMPLETE
Thursday, June 20, 2024DIVISIONAL REQUEST RECEIVED
Thursday, June 20, 2024STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

mtac development research pharmaceutical